Disappointment with the Bank of Japan's monetary policy sent the markets tumbling to a sharply lower close with the Dow plunging 116 points to 15,122. Nasdaq plummeted 36 points to 3436.
On the upside
A Food and Drug Administration advisory panel will review the constipation treatment Relistor that was developed by Progenics Pharmaceuticals (Nasdaq: PGNX) and Salix Pharmaceuticals (Nasdaq: SLXP).
Baker Bros. increased its stake in Vanda Pharmaceuticals (Nasdaq: VNDA) to 13.99%.
Diamond Foods (NYSE: DMND) narrowed third quarter losses more than expected and appointed Raymond Silcock to the position of executive vice president and chief financial officer.
On the downside
First Solar (Nasdaq: FSLR) announced a public offering of 8.5 million common shares.
Symmetry Medical (NYSE: SMA) forecast second quarter earnings and revenue below analyst expectations and cut its full year guidance.
Workday (NYSE: WDAY) will offer a total of $440 million in convertible senior notes.
In the broad market, declining issues outpaced advancers by a margin of nearly 6 to 1 on the NYSE and by more than to 5 to 2 on Nasdaq. The broader S&P 500 index tumbled 16 points to 1626.
